15,214 Shares in DexCom, Inc. (NASDAQ:DXCM) Acquired by Virtu Financial LLC

Virtu Financial LLC acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 15,214 shares of the medical device company’s stock, valued at approximately $1,020,000.

Several other large investors also recently added to or reduced their stakes in DXCM. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of DexCom during the 2nd quarter valued at about $25,000. Sachetta LLC boosted its holdings in DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 171 shares during the last quarter. Riverview Trust Co grew its stake in shares of DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares during the period. DT Investment Partners LLC increased its holdings in shares of DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after buying an additional 315 shares during the last quarter. Finally, RPg Family Wealth Advisory LLC purchased a new stake in shares of DexCom during the 3rd quarter valued at approximately $57,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DXCM has been the subject of several analyst reports. Citigroup increased their price objective on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday. Sanford C. Bernstein raised their price objective on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Raymond James lowered their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Finally, Piper Sandler restated an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a report on Monday, August 26th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus target price of $98.00.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $77.19 on Friday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The company has a market cap of $30.15 billion, a price-to-earnings ratio of 46.22, a price-to-earnings-growth ratio of 2.46 and a beta of 1.12. The stock’s 50-day moving average is $73.58 and its two-hundred day moving average is $84.99. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.